Join the club for FREE to access the whole archive and other member benefits.

Off-the-shelf natural killer cells to target solid tumours in clinical trial

Using iPS cells would be a lot cheaper than personalised immunotherapy

09-Apr-2019

Key points from article :

Immunotherapy has improved treatments melanoma, but many tumours can evade the immune system.

UC San Diego and Fate Therapeutics are running a clinical trial with natural killer cells.

Natural killer (NK) cells are specialized white blood cells able to break through cell membranes.

Targeting people with advanced solid tumours with off-the-shelf NK cells.

First trial in the U.S. to use cells derived from induced pluripotent stem (iPS) cells.

Dr. Dan Kaufman developed a method of expanding large numbers of NK cells in 2013.

Preclinical research demonstrated effective killing of cancer cells in cell culture and in mouse models.

Phase I trial started in February and will include up to 64 people with advanced, untreatable cancer.

Will test on their own as well as in combination with a checkpoint inhibitor.

The study was published in Stem Cells Translational Medicine.

Mentioned in this article:

Click on resource name for more details.

Dan Kaufman

Professor of Medicine and Director of Cell Therapy at University of California San Diego.

Fate Therapeutics

Biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders.

Stem Cells Translational Medicine (SCTM)

Journal which publish papers with topics related to translational medicine.

UC San Diego School of Medicine

School for medical and scientific training.

Topics mentioned on this page:
Cancer